Compare IVA & BZH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVA | BZH |
|---|---|---|
| Founded | 2011 | 1985 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 769.0M | 717.3M |
| IPO Year | 2020 | 1994 |
| Metric | IVA | BZH |
|---|---|---|
| Price | $4.45 | $22.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $17.14 | ★ $32.00 |
| AVG Volume (30 Days) | 233.5K | ★ 496.9K |
| Earning Date | 09-29-2025 | 01-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.52 |
| Revenue | $19,929,536.00 | ★ $2,371,555,000.00 |
| Revenue This Year | N/A | $7.40 |
| Revenue Next Year | N/A | $12.09 |
| P/E Ratio | ★ N/A | $15.09 |
| Revenue Growth | N/A | ★ 1.77 |
| 52 Week Low | $2.11 | $17.37 |
| 52 Week High | $7.98 | $32.69 |
| Indicator | IVA | BZH |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 53.02 |
| Support Level | $4.05 | $21.50 |
| Resistance Level | $4.34 | $23.85 |
| Average True Range (ATR) | 0.23 | 0.87 |
| MACD | 0.06 | 0.12 |
| Stochastic Oscillator | 83.33 | 72.68 |
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in over 13 states and over 22 metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the leading sources of revenue for the company. Key metro areas include Atlanta, Las Vegas, Los Angeles, Orlando, and Tampa. The company also focuses on land purchasing and development to support future construction efforts as well as mortgage services for its homebuyers.